Days of our Lives star Billy Flynn is set to make his The Young and the Restless debut soon, and there’s a good chance he is ...

PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...

A Long Island speech pathologist said a pioneering bio implant stopped her “horrific” rheumatoid arthritis in its tracks. Massapequa’s Dawn Steiner, 58, said even a simple handshake would ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now ...

May 14, 2025 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today ...

Co-founder and Chief Scientific Officer of Orca Bio, Nate Fernhoff, Ph.D., appointed Chief Executive Officer Co-founder and Chief Operating Officer of Orca Bio, Jeroen Bekaert, Ph.D., appointed ...

California biotech NGM Bio is slimming down as the company pivots focus, shedding around 75% of staff, pausing development of a phase 2 liver disease asset and halting further investment in ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% ...

Vor Biopharma CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available ...

May 7 (Reuters) - Bio-Techne (TECH.O), opens new tab on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other ...

Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...

(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio ...